The first transplant using cord blood-derived hematopoietic stem cells was performed in October 1988. Since that year, remarkable achievements have been made in terms of research into umbilical cord blood-derived hematopoietic and progenitor cells. More than 40,000 UCB transplants (UCBTs) have been performed across different geographies of the world, in both children and adults, to treat diseases that include hematologic, metabolic, immunologic, neoplastic, and neurologic disorders. [Read more…]
Advanced Cell Models Usher in a New Era of Neuroscience Research
Neurodegenerative diseases, like Alzheimer’s and Parkinson’s disease are caused by progressive damage to cells of the nervous system. Patients suffering from these debilitating disorders lose their mobility, balance, speech, and so many other important functions. Scientists studying these disorders need advanced cell models that have the physiological and pharmacological properties seen in mature neurons. [Read more…]
Nano-race: Industrial Landscape of Exosome-Based Therapeutics and Diagnostics
Exosomes are nano-sized vesicles ranging from 30-200nm that are present in eukaryotic fluids and facilitate a diverse range of cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells.
Because of their far ranging potential, exosomes can be commercialized as therapeutic agents, diagnostic tools, and cosmeceuticals. Today, a surging number of companies are developing exosome-based products and technologies.
Exosome Market Competitors
Currently, there are at least 45 market competitors which compose the exosome industry in therapeutics and diagnostics. Twenty six of them are companies specializing in exosomes and nineteen of them are established companies that have recently jumped into the exosome industry.
[Read more…]
Editas Medicine Granted RMAT Designation for EDIT-301 for Severe Sickle Cell Disease
October 17, 2023, CAMBRIDGE, Mass. — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to EDIT-301, an investigational, gene editing medicine, for the treatment of severe sickle cell disease (SCD). [Read more…]
Stem Cell Therapy: A New Treatment Approach In Multiple Sclerosis
Multiple sclerosis (MS) is a neurodegenerative disease with symptoms associated with impaired conduction of nerve fibers. The disease has an autoimmune nature with the own immune system attacking the myelin sheath.
Unlike other common diseases of the nervous system (dementia, Alzheimer’s disease, Parkinson’s disease) MS is not considered age-related. Multiple sclerosis affects middle-aged people, both women and men, though more often the latter. [Read more…]
- « Previous Page
- 1
- …
- 111
- 112
- 113
- 114
- 115
- …
- 336
- Next Page »